Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

Completed · Phase 2

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria (PNH)

In brief

To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan dose may be increased within each participant, to a maximum of 200 milligrams (mg) three times daily (TID) based on safety and efficacy at protocol-specified time points.

Key facts

Study ID

NCT03472885

Run by

Alexion Pharmaceuticals, Inc.

People needed

12

Starts

2018-05-08

Expected to finish

2023-01-05

Last updated by the study team

2023-12-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Study Site — Baltimore, Maryland, United States
• Clinical Study Site — Cleveland, Ohio, United States
• Clinical Study Site — Florence, Italy
• Clinical Study Site — Naples, Italy
• Clinical Study Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.